Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
58 studies found for:    Open Studies | "Waldenstrom Macroglobulinemia"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Waldenstrom Macroglobulinemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Ixazomib;   Drug: Dexamethasone;   Drug: Rituximab
2 Recruiting Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Ibrutinib
3 Recruiting Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: ABT199
4 Recruiting Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Condition: Waldenström's Macroglobulinemia
Interventions: Drug: Dexamethasone, Rituximab, Cyclophosphamide;   Drug: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
5 Recruiting Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Other: autologous stem cell transplantation;   Other: conventional chemotherapy
6 Recruiting The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Rituximab
7 Recruiting Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Bortezomib-Rituximab-Bendamustine
8 Not yet recruiting Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Interventions: Drug: Obinutuzumab;   Drug: Idelalisib
9 Recruiting Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Intervention: Biological: Blood or bone marrow samples
10 Recruiting The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
Condition: Waldenström Macroglobulinemia
Intervention: Drug: Thalidomide
11 Recruiting Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
Conditions: Lymphoma;   Lymphoplasmacytic Lymphoma;   Waldenström Macroglobulinemia
Intervention: Biological: DNA Vaccine
12 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
13 Recruiting PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia
Condition: Treatment
Interventions: Drug: rituximab /Dexamethasone/cyclophosphamide;   Drug: Velcade/Dexamethasone/cyclophosphamide
14 Not yet recruiting Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Conditions: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom's Macroglobulinemia;   Mantle Zone Lymphoma Refractory/Recurrent;   Follicle Centre Lymphoma Diffuse;   Diffuse Large B Cell Lymphoma
Intervention: Drug: CT-1530
15 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia;   Lymphoplasmacytic Lymphoma;   Waldenstrom Macroglobulinemia;   Splenic Marginal Zone Lymphoma
Intervention:
16 Recruiting BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
Conditions: B-cell Lymphoma;   Chronic Lymphocytic Leukaemia;   Waldenström Macroglobulinaemia
Interventions: Biological: BI-1206 single agent dose escalation phase;   Biological: BI-1206 single agent expansion phase;   Biological: Combination of BI-1206 with Rituximab
17 Recruiting Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
Conditions: Waldenstrom Macroglobulinemia;   Chronic Lymphocytic Leukemia;   Hodgkin Disease;   NonHodgkin Lymphoma;   Mixed Lymphoproliferative Disease
Intervention:
18 Recruiting Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Conditions: Recurrent Chronic Lymphocytic Leukemia;   Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Nodal Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Splenic Marginal Zone Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Nodal Marginal Zone Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Refractory Splenic Marginal Zone Lymphoma;   Richter Syndrome;   Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Idelalisib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
19 Not yet recruiting Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Mediastinal Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Waldenstrom Macroglobulinemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
20 Recruiting Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic-Myeloproliferative Diseases;   Hematological Malignancies;   B-cell Malignancy, Low-grade;   Myelodysplastic Syndrome With Low-grade Lesions;   IgG Monoclonal Gammopathy of Uncertain Significance;   Smoldering Multiple Myeloma;   Waldenstrom Macroglobulinemia
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.